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Hospital Discharge 
Data for Guillain-
Barré Syndrome 
and Inﬂ  uenza A 
(H1N1) Vaccine 
Adverse Events 
To the Editor: As part of the 
public health response to the current 
pandemic (H1N1) 2009, surveillance 
for adverse events following vac-
cination for inﬂ   uenza A (H1N1) is 
a high priority (1). Surveillance for 
Guillain-Barré syndrome (GBS) has 
been of particular interest, because 
the syndrome was associated with the 
1976–1977 swine inﬂ  uenza vaccine 
(1,2). To study this association, reli-
able ascertainment of recent incident 
cases of GBS is necessary. 
GBS is an acute, immune-me-
diated paralytic disorder of the pe-
ripheral nervous system (3–5) with 
an estimated annual incidence of 
0.8–1.9/100,000 (6). Most cases are 
associated with an antecedent infec-
tion (6). Several surveillance systems 
are in place to monitor rates of post-
vaccination GBS (1–3), most of which 
include a component of electronic 
administrative record review for case 
detection. Analysis of computerized 
medical databases is a well-established 
method of monitoring for vaccine ad-
verse events (7). Although the validity 
of such data varies, depending on the 
diagnosis and region, few studies have 
evaluated the use of hospital discharge 
data for GBS speciﬁ  cally (8,9).
We reviewed the Tennessee De-
partment of Health Uniform Hospi-
tal Discharge Dataset for all hospi-
tal discharge diagnoses in 4 major 
metropolitan regions of Tennessee in 
2002–2003 with codes from the In-
ternational Classiﬁ  cation of Diseases, 
9th Revision, Clinical Modiﬁ  cation 
(ICD-9-CM), that might indicate acute 
GBS. Records with ICD-9-CM code 
357.0 (acute infective polyneuritis) 
or other combinations suggestive of 
GBS within the top 10 diagnoses were 
requested. These data were compared 
with information on cases identiﬁ  ed 
by directly requesting lists of patients 
with discharge diagnoses of GBS from 
hospital medical record departments. 
Charts of all reported cases were vali-
dated by chart review. Patients were 
classiﬁ  ed as having acute GBS if they 
met Brighton Criteria Levels 1, 2, or 
3 (10).
A total of 344 records of possible 
cases of acute GBS were identiﬁ  ed. Of 
these cases, 215 (63%) were identiﬁ  ed 
through the state hospital discharge 
database, 315 (92%) were reported 
directly by hospitals, and 186 (54%) 
were identiﬁ   ed by both systems. 
Among all suspected cases identiﬁ  ed, 
only 103 (30%) met criteria for acute 
GBS (annual rate 2.1/100,000 popu-
lation), 14 (4%) were in out-of-state 
residents, 114 (33%) were nonacute 
cases that occurred before the study 
period and patients were readmitted 
for other reasons, 90 (26%) had no 
documentation of GBS in the medi-
cal record, 17 (5%) were duplicate 
reports, and 6 (2%) had insufﬁ  cient 
information for further investigation. 
The predictive-value positive of a 
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GBS diagnostic code from the state-
wide hospital discharge database rep-
resenting acute GBS was only 30%. 
Of the 103 conﬁ  rmed cases, 26 (25%) 
would have been missed if only the 
state hospital discharge database was 
used to identify potential cases.
Of 103 cases, all were identi-
ﬁ  ed with ICD-9-CM diagnosis code 
357.0; in 91 (88%) cases, this was the 
primary diagnosis. Other combina-
tions of codes did not identify addi-
tional cases. Of cases of acute GBS 
identiﬁ  ed, 32 (30%) met only clinical 
criteria (Brighton Level 1), 40 (39%) 
had either laboratory or electrophysi-
ologic evidence (Brighton Level 2), 
and 32 (31%) had both (Brighton 
Level 3).
Because the 2 surveillance sys-
tems we compared both relied on 
medical record discharge diagnoses, 
they were not independent, and we 
could not perform a capture/recap-
ture analysis. Because GBS is a di-
agnosis for which the great majority 
of patients are hospitalized, and our 
overall incidence rate is within the 
range identiﬁ  ed in other studies, it is 
likely that the combination of these 
methods is reasonably sensitive. The 
administrative hospital discharge da-
tabase could not be relied on to con-
ﬁ  rm that all coded GBS cases were 
acute. Even if the 114 nonacute cases 
could easily have been identiﬁ  ed and 
excluded from the initial list of 344 
records, only 103 (45%) of the re-
maining 230 reports were identiﬁ  ed 
as conﬁ  rmed acute cases.
Although the use of large hospital 
discharge databases may be useful as 
an adjunct for identiﬁ  cation of GBS 
cases as part of public health surveil-
lance, they lack sufﬁ  cient sensitivity 
or speciﬁ   city to be relied upon ex-
clusively. The poor speciﬁ  city of the 
system is particularly problematic for 
public health surveillance. A large in-
vestment of time and resources was 
necessary to perform manual chart re-
views to conﬁ  rm possible cases, two-
thirds of which were ultimately found 
not to be cases at all. Statewide admin-
istrative hospital discharge diagnosis 
databases should not be solely relied 
on for GBS surveillance. Additional 
methods of reliable and efﬁ  cient as-
certainment and veriﬁ  cation of cases 
are crucial to ensure valid data. Ob-
taining reliable methods is particularly 
important for urgent situations such as 
current surveillance for adverse events 
after pandemic (H1N1) 2009 virus 
vaccination, in which the detection of 
problems will have immediate public 
health effects.
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Contact Lens 
Solution–associated 
Acanthamoeba and 
Fusarium Keratitis
To the Editor: Verani et al. (1) 
detailed the 2004–2007 outbreak of 
Acanthamoeba keratitis (AK) in per-
sons wearing soft contact lenses who 
used Complete MoisturePlus (CMP) 
multipurpose contact lens solution 
(Advanced Medical Optics, Santa 
Ana, CA, USA). They noted similari-
ties between the AK outbreak and the 
Fusarium keratitis (FK) outbreak of 
2004–2006, including the concomi-
tant time frame and association with a 
particular solution, ReNu with Mois-
tureLoc (Bausch & Lomb, Rochester, 
NY, USA). Both solutions were new 
products introduced within 1 year be-
fore the respective outbreaks.
In neither outbreak was the solu-
tion contaminated; in both outbreaks, 
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